ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cub...( Expanding chemistry and introducing...)

Expanding chemistry and introducing continuous process chemistry to the

next generation of chemists among the goals

BUDAPEST, Hungary, LONDON and PRINCETON, N.J., Oct. 6 /PRNewswire/ -- ThalesNano, Inc. today announced that it has signed agreements with a number of academic organizations including the Scripps Research Institute, the University of California, San Francisco, Boston University, Temple University and the University of Texas at Arlington. These institutions join the top 20 pharmaceutical companies, who have all deployed ThalesNano's H-Cube.

The H-Cube Hydrogenation Reactor is a bench-top standalone device, uniquely combining continuous-flow chemistry with endogenous hydrogen generation and a disposable catalyst cartridge system. At about a foot wide, and with the flexibility to use a vastly extended range of conditions compared to traditional techniques without any safety concerns, the H-Cube system is ideally suited to educational and to academic research laboratories.

Professor Phil Baran of the Scripps Research Institute explains, "The H-Cube has already had a dramatic effect on our research and that of several groups at Scripps. We believe the H-Cube will soon be as essential as an HPLC in the toolkit of a modern organic chemistry laboratory."

Added Dr. Chris O'Brien of the University of Texas at Arlington, "My group now take for granted that they can perform high pressure, high temperature hydrogenations with ease in a fume hood. To do these reactions conventionally requires substantial safety precautions and training. As testament to the H-Cube Midi's ease-of-use and scalability, high pressure hydrogenations are now routinely performed by undergraduates to yield 10s of grams of final product. H-Cube technology is a must-have for any synthetic laboratory."

"We believe that collaboration with leading universities will serve the entire chemistry community," said Dr. Laszlo Urge, CEO of ThalesNa
'/>"/>